Transgene Sa Stock Today
| TRGNF Stock | USD 1.59 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 85
|
Transgene is trading at 1.59 as of the 22nd of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 1.59. Transgene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Transgene SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. The company has 100.2 M outstanding shares. More on Transgene SA
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Transgene Pink Sheet Highlights
| President | Eric Quemeneur |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Transgene SA [TRGNF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 212.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Transgene's market, we take the total number of its shares issued and multiply it by Transgene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Transgene SA classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 100.2 M outstanding shares.
Transgene SA has accumulated about 49.57 M in cash with (31.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check Transgene Probability Of Bankruptcy
Ownership AllocationTransgene SA shows a total of 100.2 Million outstanding shares. About 98.3 % of Transgene outstanding shares are held by general public with 1.7 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Transgene Ownership Details
Transgene Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Transgene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Transgene Corporate Management
| Maud MD | VP Officer | Profile | |
| Gaelle Stadtler | VP HR | Profile | |
| Hedi Brahim | CEO Director | Profile | |
| Lucie Larguier | Director IR | Profile |
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.